FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer

Figure 1 Progression-free survival (A) and overall survival (B) hazard ratios of ¹⁸F-fluorodeoxyglucose measured by positron emission tomography metabolic responders over the metabolic nonresponders with 95%CI based on the results from previous studies. The groups over the dotted line represent the data of early phase evaluation (2 d, 1 wk or 2 wk) and the groups under the dotted line represent the data of late phase evaluation (6 wk or 8 wk) after the initiation of epidermal growth factor receptor-tyrosine kinase inhibitor therapy. The data were available from references of [23,25,26].